Persistent staphylococcus aureus bacteremia: A prospective analysis of risk factors, outcomes, and microbiologic and genotypic characteristics of isolates

Medicine (United States)

Volumn 92, Issue 2, 2013, Pages 98-108

  Chong, Yong Pil ^a   Park, Su Jin ^a   Kim, Hee Sueng ^a   Kim, Eun Sil ^a   Kim, Mi Na ^a   Park, Ki Ho ^a   Kim, Sung Han ^a   Lee, Sang Oh ^a   Choi, Sang Ho ^a   Jeong, Jin Yong ^a   Woo, Jun Hee ^a   Kim, Yang Soo ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

DAPTOMYCIN; LINEZOLID; TEICOPLANIN; VANCOMYCIN;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; ATTRIBUTABLE RISK; BACTERIAL ENDOCARDITIS; BACTERIAL GENE; BACTERIAL VIRULENCE; BACTERIUM ISOLATE; BLOOD CULTURE; BONE INFECTION; CASE CONTROL STUDY; CATHETER INFECTION; CENTRAL NERVOUS SYSTEM INFECTION; CENTRAL VENOUS CATHETER; COHORT ANALYSIS; CONTROLLED STUDY; ENDOPHTHALMITIS; FEMALE; FOLLOW UP; GENOTYPE; HUMAN; INFECTION RISK; INFECTIOUS ARTHRITIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; MULTILOCUS SEQUENCE TYPING; NONHUMAN; OUTCOME ASSESSMENT; PENICILLIN RESISTANCE; PERSISTENT INFECTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RELAPSE; SKIN INFECTION; SOFT TISSUE INFECTION; STAPHYLOCOCCAL BACTEREMIA; STAPHYLOCOCCUS AUREUS; TERTIARY HEALTH CARE;

AGED; BACTEREMIA; CASE-CONTROL STUDIES; FEMALE; GENES, BACTERIAL; GENOTYPE; HUMANS; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MIDDLE AGED; PROSPECTIVE STUDIES; REPUBLIC OF KOREA; RISK FACTORS; STAPHYLOCOCCAL INFECTIONS; TREATMENT OUTCOME;

EID: 84874936592     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0b013e318289ff1e     Document Type: Article

References (59)

1. Ammerlaan H, Seifert H, Harbarth S, Brun-Buisson C, Torres A, Antonelli M, Kluytmans J, Bonten M. Adequacy of antimicrobial treatment and outcome of Staphylococcus aureus bacteremia in 9 Western European countries. Clin Infect Dis. 2009;49: 997-1005.
2. Bae IG, Federspiel JJ, Miro JM, Woods CW, Park L, Rybak MJ, Rude TH, Bradley S, Bukovski S, de la Maria CG, Kanj SS, Korman TM, Marco F, Murdoch DR, Plesiat P, Rodriguez-Creixems M, Reinbott P, Steed L, Tattevin P, Tripodi MF, Newton KL, Corey GR, Fowler VG. Heterogeneous vancomycin-intermediate susceptibility phenotype in bloodstream methicillin-resistant Staphylococcus aureus isolates from an international cohort of patients with infective endocarditis: prevalence, genotype, and clinical significance. J Infect Dis. 2009;200: 1355-1366.
3. Bubeck Wardenburg J, Palazzolo-Ballance AM, Otto M, Schneewind O, DeLeo FR. Panton-Valentine leukocidin is not a virulence determinant in murine models of community-associated methicillin-resistant Staphylococcus aureus disease. J Infect Dis. 2008;198: 1166-1170.
4. Campbell SJ, Deshmukh HS, Nelson CL, Bae IG, Stryjewski ME, Federspiel JJ, Tonthat GT, Rude TH, Barriere SL, Corey R, Fowler VG. Genotypic characteristics of Staphylococcus aureus isolates from a multinational trial of complicated skin and skin structure infections. J Clin Microbiol. 2008;46: 678-684. (Pubitemid 351231317)
5. Chang FY, MacDonald BB, Peacock JE, Musher DM, Triplett P, Mylotte JM, O'Donnell A, Wagener MM, Yu VL. A prospective multicenter study of Staphylococcus aureus bacteremia: incidence of endocarditis, risk factors for mortality, and clinical impact of methicillin resistance. Medicine (Baltimore). 2003;82: 322-332. (Pubitemid 37229467)
6. Charlson M, Pompei P, Ales K, MacKenzie C. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40: 373-383. (Pubitemid 17055592)
7. Chow J, Fine M, Shlaes D, Quinn J, Hooper D, Johnson M, Ramphal R, Wagener M, Miyashiro D, Yu V. Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. Ann Intern Med. 1991;115: 585-590.
8. David MZ, Glikman D, Crawford SE, Peng J, King KJ, Hostetler MA, Boyle-Vavra S, Daum RS. What is community-associated methicillin-resistant Staphylococcus aureus? J Infect Dis. 2008;197: 1235-1243. (Pubitemid 351632754)
9. Deresinski S. Methicillin-resistant Staphylococcus aureus and vancomycin: minimum inhibitory concentration matters. Clin Infect Dis. 2012;54: 772-774.
10. Diep BA, Carleton HA, Chang RF, Sensabaugh GF, Perdreau-Remington F. Roles of 34 virulence genes in the evolution of hospital- and community-associated strains of methicillin-resistant Staphylococcus aureus. J Infect Dis. 2006;193: 1495-1503. (Pubitemid 43794577)
11. Enright MC, Day NP, Davies CE, Peacock SJ, Spratt BG. Multilocus sequence typing for characterization of methicillin-resistant and methicillin- susceptible clones of Staphylococcus aureus. J Clin Microbiol. 2000;38: 1008-1015. (Pubitemid 30140551)
12. Fowler VG, Nelson CL, McIntyre LM, Kreiswirth BN, Monk A, Archer GL, Federspiel J, Naidich S, Remortel B, Rude T, Brown P, Reller LB, Corey GR, Gill SR. Potential associations between hematogenous complications and bacterial genotype in Staphylococcus aureus infection. J Infect Dis. 2007;196: 738-747. (Pubitemid 47293857)
13. Fowler VG, Olsen MK, Corey GR, Woods CW, Cabell CH, Reller LB, Cheng AC, Dudley T, Oddone EZ. Clinical identifiers of complicated Staphylococcus aureus bacteremia. Arch Intern Med. 2003;163: 2066-2072. (Pubitemid 37151249)
14. Fowler VG, Sakoulas G, McIntyre LM, Meka VG, Arbeit RD, Cabell CH, Stryjewski ME, Eliopoulos GM, Reller LB, Corey GR, Jones T, Lucindo N, Yeaman MR, Bayer AS. Persistent bacteremia due to methicillin-resistant Staphylococcus aureus infection is associated with agr dysfunction and low-level in vitro resistance to thrombin-induced platelet microbicidal protein. J Infect Dis. 2004;190: 1140-1149. (Pubitemid 39186802)
15. Friedman N, Kaye K, Stout J, McGarry S, Trivette S, Briggs J, Lamm W, Clark C, MacFarquhar J, Walton A, Reller L, Sexton D. Health care-associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections. Ann Intern Med. 2002;137: 791-797. (Pubitemid 35334450)
16. Garner J, Jarvis W, Emori T, Horan T, Hughes J. CDC definitions for nosocomial infections, 1988. Am J Infect Control. 1988;16: 128-140.
17. Hageman JC, Liedtke LA, Sunenshine RH, Strausbaugh LJ, McDonald LC, Tenover FC. Management of persistent bacteremia caused by methicillin-resistant Staphylococcus aureus: a survey of infectious diseases consultants. Clin Infect Dis. 2006;43:e42-e45.
18. Hawkins C, Huang J, Jin N, Noskin GA, Zembower TR, Bolon M. Persistent Staphylococcus aureus bacteremia: an analysis of risk factors and outcomes. Arch Intern Med. 2007;167: 1861-1867. (Pubitemid 47481481)
19. Hidayat LK, Hsu DI, Quist R, Shriner KA,Wong-Beringer A. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med. 2006;166: 2138-2144. (Pubitemid 44631403)
20. Howden BP, Johnson PD, Ward PB, Stinear TP, Davies JK. Isolates with low-level vancomycin resistance associated with persistent methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob Agents Chemother. 2006;50: 3039-3047. (Pubitemid 44396410)
21. Jarraud S, Mougel C, Thioulouse J, Lina G, Meugnier H, Forey F, Nesme X, Etienne J, Vandenesch F. Relationships between Staphylococcus aureus genetic background, virulence factors, agr groups (alleles), and human disease. Infect Immun. 2002;70: 631-641. (Pubitemid 34083822)
22. Jensen AG, Wachmann CH, Espersen F, Scheibel J, Skinhøj P, Frimodt-Møller N. Treatment and outcome of Staphylococcus aureus bacteremia: a prospective study of 278 cases. Arch Intern Med. 2002;162: 25-32. (Pubitemid 34073396)
23. Khatib R, Johnson LB, Fakih MG, Riederer K, Khosrovaneh A, Shamse Tabriz M, Sharma M, Saeed S. Persistence in Staphylococcus aureus bacteremia: incidence, characteristics of patients and outcome. Scand J Infect Dis. 2006;38: 7-14. (Pubitemid 43123837)
24. Khatib R, Johnson LB, Sharma M, Fakih MG, Ganga R, Riederer K. Persistent Staphylococcus aureus bacteremia: incidence and outcome trends over time. Scand J Infect Dis. 2009;41: 4-9.
25. Khatib R, Jose J, Musta A, Sharma M, Fakih MG, Johnson LB, Riederer K, Shemes S. Relevance of vancomycin-intermediate susceptibility and heteroresistance in methicillin-resistant Staphylococcus aureus bacteraemia. J Antimicrob Chemother. 2011;66: 1594-1599.
26. Khosrovaneh A, Riederer K, Saeed S, Tabriz MS, Shah AR, Hanna MM, Sharma M, Johnson LB, Fakih MG, Khatib R. Frequency of reduced vancomycin susceptibility and heterogeneous subpopulation in persistent or recurrent methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis. 2004;38: 1328-1330. (Pubitemid 38608580)
27. Kim ES, Song JS, Lee HJ, Choe PG, Park KH, Cho JH, Park WB, Kim SH, Bang JH, Kim DM, Park KU, Shin S, Lee MS, Choi HJ, Kim NJ, Kim EC, Oh MD, Kim HB, Choe KW. A survey of community-associated methicillin-resistant Staphylococcus aureus in Korea. J Antimicrob Chemother. 2007;60: 1108-1114. (Pubitemid 47617762)
28. Kullar R, Davis SL, Levine DP, Rybak MJ. Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggested targets. Clin Infect Dis. 2011;52: 975-981.
29. Lalani T, Federspiel JJ, Boucher HW, Rude TH, Bae IG, Rybak MJ, Tonthat GT, Corey GR, Stryjewski ME, Sakoulas G, Chu VH, Alder J, Steenbergen JN, Luperchio SA, Campion M, Woods CW, Fowler VG. Associations between the genotypes of Staphylococcus aureus bloodstream isolates and clinical characteristics and outcomes of bacteremic patients. J Clin Microbiol. 2008;46: 2890-2896.
30. Li JS, Sexton DJ, Mick N, Nettles R, Fowler VG, Ryan T, Bashore T, Corey GR. Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis. Clin Infect Dis. 2000;30: 633-638.
31. Li M, Cheung GY, Hu J, Wang D, Joo HS, Deleo FR, Otto M. Comparative analysis of virulence and toxin expression of global community-associated methicillin-resistant Staphylococcus aureus strains. J Infect Dis. 2010;202: 1866-1876.
32. Lin SH, Liao WH, Lai CC, Liao CH, Tan CK, Wang CY, Huang YT, Hsueh PR. Risk factors for mortality in patients with persistent methicillin-resistant Staphylococcus aureus bacteraemia in a tertiary care hospital in Taiwan. J Antimicrob Chemother. 2010;65: 1792-1798.
33. Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, Kaplan SL, Karchmer AW, Levine DP, Murray BE, J Rybak M, Talan DA, Chambers HF. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011;52:e18-e55.
34. Lodise TP, Graves J, Evans A, Graffunder E, Helmecke M, Lomaestro BM, Stellrecht K. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob Agents Chemother. 2008;52: 3315-3320.
35. Lodise TP, Lomaestro B, Graves J, Drusano GL. Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob Agents Chemother. 2008;52: 1330-1336. (Pubitemid 351521995)
36. McCabe WR, Jackson GG. Gram-negative bacteremia: I. Etiology and ecology. Arch Intern Med. 1962;110: 847-855.
37. Mermel LA, Allon M, Bouza E, Craven DE, Flynn P, O'Grady NP, Raad II, Rijnders BJ, Sherertz RJ, Warren DK. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2009;49: 1-45.
38. Mermel LA, Farr BM, Sherertz RJ, Raad II, O'Grady N, Harris JS, Craven DE. Guidelines for the management of intravascular catheter-related infections. Clin Infect Dis. 2001;32: 1249-1272. (Pubitemid 32405897)
39. Musta AC, Riederer K, Shemes S, Chase P, Jose J, Johnson LB, Khatib R. Vancomycin MIC plus heteroresistance and outcome of methicillin-resistant Staphylococcus aureus bacteremia: trends over 11 years. J Clin Microbiol. 2009;47: 1640-1644.
40. Neuner EA, Casabar E, Reichley R, McKinnon PS. Clinical, microbiologic, and genetic determinants of persistent methicillin-resistant Staphylococcus aureus bacteremia. Diagn Microbiol Infect Dis. 2010;67: 228-233.
41. Nolan CM, Beaty HN. Staphylococcus aureus bacteremia. Current clinical patterns. Am J Med. 1976;60: 495-500.
42. Oliveira DC, de Lencastre H. Multiplex PCR strategy for rapid identification of structural types and variants of the mec element in methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2002;46: 2155-2161. (Pubitemid 34665910)
43. Patel N, Pai MP, Rodvold KA, Lomaestro B, Drusano GL, Lodise TP. Vancomycin: we can't get there from here. Clin Infect Dis. 2011;52: 969-974.
44. Paul M, Kariv G, Goldberg E, Raskin M, Shaked H, Hazzan R, Samra Z, Paghis D, Bishara J, Leibovici L. Importance of appropriate empirical antibiotic therapy for methicillin-resistant Staphylococcus aureus bacteraemia. J Antimicrob Chemother. 2010;65: 2658-2665.
45. Peacock SJ, Moore CE, Justice A, Kantzanou M, Story L, Mackie K, O'Neill G, Day NP. Virulent combinations of adhesin and toxin genes in natural populations of Staphylococcus aureus. Infect Immun. 2002;70: 4987-4996.
46. Rybak M, Lomaestro B, Rotschafer JC, Moellering R, Craig W, Billeter M, Dalovisio JR, Levine DP. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm. 2009;66: 82-98.
47. Schweizer ML, Furuno JP, Sakoulas G, Johnson JK, Harris AD, Shardell MD, McGregor JC, Thom KA, Perencevich EN. Increased mortality with accessory gene regulator (agr) dysfunction in Staphylococcus aureus among bacteremic patients. Antimicrob Agents Chemother. 2011;55: 1082-1087.
48. Seidl K, Bayer AS, Fowler VG, McKinnell JA, Abdel Hady W, Sakoulas G, Yeaman MR, Xiong YQ. Combinatorial phenotypic signatures distinguish persistent from resolving methicillin-resistant Staphylococcus aureus bacteremia isolates. Antimicrob Agents Chemother. 2011;55: 575-582.
49. Shorr AF, Tabak YP, Killian AD, Gupta V, Liu LZ, Kollef MH. Healthcare-associated bloodstream infection: a distinct entity? Insights from a large U.S. database. Crit Care Med. 2006;34: 2588-2595. (Pubitemid 44413057)
50. Siegman-Igra Y, Reich P, Orni-Wasserlauf R, Schwartz D, Giladi M. The role of vancomycin in the persistence or recurrence of Staphylococcus aureus bacteraemia. Scand J Infect Dis. 2005;37: 572-578.
51. Soriano A, Marco F, Martinez JA, Pisos E, Almela M, Dimova VP, Alamo D, Ortega M, Lopez J, Mensa J. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis. 2008;46: 193-200. (Pubitemid 351269157)
52. Soriano A, Martinez JA, Mensa J, Marco F, Almela M, Moreno-Martinez A, Sanchez F, Munoz I, Jimenez de Anta MT, Soriano E. Pathogenic significance of methicillin resistance for patients with Staphylococcus aureus bacteremia. Clin Infect Dis. 2000;30: 368-373. (Pubitemid 30131548)
53. van Hal SJ, Lodise TP, Paterson DL. The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis. Clin Infect Dis. 2012;54: 755-771.
54. Walraven CJ, North MS, Marr-Lyon L, Deming P, Sakoulas G, Mercier RC. Site of infection rather than vancomycin MIC predicts vancomycin treatment failure in methicillin-resistant Staphylococcus aureus bacteraemia. J Antimicrob Chemother. 2011;66: 2386-2392.
55. Walsh TR, Bolmstrom A, Qwarnstrom A, Ho P, Wootton M, Howe RA, MacGowan AP, Diekema D. Evaluation of current methods for detection of staphylococci with reduced susceptibility to glycopeptides. J Clin Microbiol. 2001;39: 2439-2444. (Pubitemid 32606216)
56. Wootton M, Howe RA, Hillman R, Walsh TR, Bennett PM, MacGowan AP. A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital. J Antimicrob Chemother. 2001;47: 399-403. (Pubitemid 32303403)
57. Wyllie DH, Crook DW, Peto TE. Mortality after Staphylococcus aureus bacteraemia in two hospitals in Oxfordshire, 1997Y2003: cohort study. BMJ. 2006;333:281.
58. Xiong YQ, Fowler VG, Yeaman MR, Perdreau-Remington F, Kreiswirth BN, Bayer AS. Phenotypic and genotypic characteristics of persistent methicillin-resistant Staphylococcus aureus bacteremia in vitro and in an experimental endocarditis model. J Infect Dis. 2009;199: 201-208.
59. Yoon YK, Kim JY, Park DW, Sohn JW, Kim MJ. Predictors of persistent methicillin-resistant Staphylococcus aureus bacteraemia in patients treated with vancomycin. J Antimicrob Chemother. 2010;65: 1015-1018.